Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.40 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14238796 | 0.89 | TK1 (0.42) | TK1TK2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14217398 | 0.87 | TK1 (0.36) | TK1TK2BCHE | |
| SCHEMBL14217403 | 0.81 | TERT (0.35) | TK1TK2 | |
| SCHEMBL14217396 | 0.81 | TK1 (0.44) | TK1TK2BCHELMNAALDH1A1 | |
| SCHEMBL9780930 | 0.80 | TK1 (0.45) | TK1TK2BCHE | |
| SCHEMBL9780924 | 0.80 | TK1 (0.45) | TK1TK2BCHE | |
| SCHEMBL13019211 | 0.78 | TK1 (0.54) | TK1BCHELMNAALDH1A1POLB | |
| SCHEMBL16552337 | 0.78 | TK1 (0.54) | TK1BCHELMNAALDH1A1POLB | |
| SCHEMBL10522597 | 0.77 | TK1 (0.56) | TK1TK2BCHELMNAALB | |
| SCHEMBL10522602 | 0.77 | TK1 (0.56) | TK1TK2BCHELMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | Life Technologies Corporation (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | PNP, NUDT1, DUT | TK1 85/4885TK2 112/4885BCHE 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.